Press release
Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI*
-- When Combined with Recently Announced $75M Royalty Financing, the Company Will Have Access to ~$150M of Non-Dilutive Capital for Launch of MOLBREEVI --
About this update from Savara, Inc.
[{"type":"text","content":"\n-- When Combined with Recently Announced $75M Royalty Financing, the Company Will Have Access to ~$150M of Non-Dilutive Capital for Launch of MOLBREEVI --\n\n\n LANGHORNE, Pa.--(BUSINESS WIRE)--\nSavara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the amendment of its loan and security agreement with Hercules Capital, Inc. (NYSE:HTGC), strengthening its balance sheet and liquidity.\n\n\nUnder the terms of the amended loan agreement, up to an additional $75 million will become available upon FDA’s approval of MOLBREEVI, the Company’s investigational therapy in autoimmune pulmonary alveolar proteinosis (autoimmune PAP). The loan agreement maturity date and interest-only period remain unchanged. There are no warrants in connection with the agreement.\n\n\n“In anticipation of the potential approval of MOLBREEVI later this year, Savara will be well capitalized with ~$150 million of non-dilutive capital to support launch activities,” said Dave Lowrance, Chief Financial and Administrative Officer, Savara. “This includes the amended debt facility announced today combined with the strategic royalty financing from RTW announced in October last year.”\n\n\n“Hercules Capital is thrilled to continue our partnership with Savara as they prepare for the potential launch of MOLBREEVI,” said Tom Hertzberg, Managing Director, Hercules Capital.\n\n\nThe Company resubmitted the MOLBREEVI Biologics License Application (BLA) to the FDA in December 2025. If Priority Review is granted, MOLBREEVI could potentially be approved in 3Q 2026. The Company remains on track to file the Marketing Authorization Applications (MAA) for MOLBREEVI in Europe and the U.K. by the end of 1Q 2026.\n\n\nIn October 2025, Savara announced its entry into a $75 million royalty funding agreement, subject to FDA approval of MOLBREEVI, with RTW to support the potential launch of MOLBREEVI.\n\n\n“We have shown strong operational excellence over the last few quarters and believe that positive momentum will continue,” said Matt Pauls, Chair and Chief Executive Officer, Savara. “The Company resubmitted the MOLBREEVI BLA to the FDA, completed a U.S. claims analysis that found the autoimmune PAP market to be ~50% larger than previously estimated, and closed strategic equity and royalty financings. W...